Introduction {#Sec1}
============

The infections caused by viral pathogens including clinical viruses or naturally emerging viruses pose a serious threat worldwide. Unfortunately, only few therapeutics are available for limited viruses like Human immunodeficiency virus (HIV), Hepatitis virus, Herpes simplex virus (HSV) and Influenza virus (Rider et al. [@CR104]). Researchers are currently working to extend the range of specific and novel antivirals to other families of pathogens. Since, viruses depend on host cell organism for replication, the selection of target for the designing of effective and safe antiviral drugs without harming the host cell, is an extremely difficult process. Besides this, owing to the evolution, mutations occur in the viral genome, which contribute to the development of resistance to drugs and thus rendered many drugs ineffective (Lee et al. [@CR66]). The peptides can block infection by targeting either virus or its host. The virus specific antiviral peptides are known as virucidal, as they directly target the viral proteins. Most of the antivirals have been reported to inhibit the development of viruses by targeting its specific regions or components. Various steps of viral life cycle have been targeted for the discovery of novel antiviral drugs, such as viral entry, viral synthesis, or assembly. Due to the extracellular site of action and blockage of viral infection, the viral entry inhibition is marked as an attractive strategy (Chew et al. [@CR29]). Protein--protein interactions (PPIs) are the foundation of important cellular processes and are considered as primary targets for the drug discovery over the last decade (Lee et al. [@CR66]; Teissier et al. [@CR120]). The knowledge of crucial interactors involved in PPIs and their mechanism is necessary to pave way for the selection of suitable target for drug discovery. New approaches in therapeutics include the use of small cyclic molecules, proteins/peptides, nucleic acids such as small interfering RNA (siRNA) and small hairpin RNA (shRNA) molecules (Teissier et al. [@CR120]). Among these advanced approaches, peptides as therapeutics is a promising field in the drug discovery (Lau and Dunn [@CR65]). Peptides are the biologically active molecules composed of amino acids residues that disrupt the PPIs. They are small (less than 100 amino acids), and they can be easily synthesized. They are also highly specific and effective even in nanomolar range. The main benefit of using peptide as therapeutics is its hydrolysis by peptidases present in the body, which prevents its accumulation in specific organs and minimizes the toxic side effects (Ali et al. [@CR6]). Previously, the pharmaceutical industries have shown poor interest for the expansion of peptide-based therapeutics because of their extremely poor ADME (absorption, distribution, metabolism and elimination) properties. However, the advanced research enables modifications of the peptides such as synthesis of amino acid enantiomers, addition of chemical compounds and their nanoparticle formulation to overcome the pharmacodynamic flaws of peptides (Gentilucci et al. [@CR44]; Zeng et al. [@CR143]). The advantages offered by the modified peptides have sparked the interest amongst the researchers and companies. Now-a-days peptide as therapeutics has come to forte with nearly 20 new peptides added in clinical trials annually. In fact, the global market of peptides as drugs has reached to billion dollars with currently more than 60 peptides approved by US Food and Drug Administration (FDA) and over 400 peptides being under clinical phase trials (Lau and Dunn [@CR65]). Peptide as therapeutics are approved or are being considered for the treatment of diseases such as cancer, diabetes, cardiovascular diseases and even infection caused by few viruses such as HIV, Herpes, Hepatitis and Influenza virus. Thus, over the years peptide-based therapeutics has added a new dimension as the potential antiviral candidate. This review focuses on the types of peptides approaches that can be used for the identification of the lead peptides against the target protein and the selected advanced techniques reported for the validation of the peptide binding affinity to their targets.

Antiviral Peptides as Therapeutics {#Sec2}
==================================

The peptides possessing potential to inhibit the virus are considered as antiviral peptides (AVPs). Usually, the AVPs exhibit antiviral effects by inhibiting the virus directly, but their inhibition sites and the mechanism of action vary within the viral replication cycle (Rider et al. [@CR104]). The AVPs can be obtained through different approaches: (1) Computational approach (2) Natural sources and (3) Biological source such as High-throughput screening (Fig. [1](#Fig1){ref-type="fig"}). There are many online databases available which contain information regarding experimentally tested antiviral peptides such as Antiviral peptide database (AVPdp) (Qureshi et al. [@CR100]) where 2683 entries of peptides including 624 modified AVPs are compiled till December 2019, while many others are unreported. Since the field of peptides as antiviral is not entirely explored, therefore, many research studies are being undertaken to elucidate the role of peptides in blocking viral infections. The first peptide drug approved for clinical indication, Enfuvirtide (Enf), a 36-amino acid residue peptide, against HIV corresponds to the heptad-repeat (HR2) domain of gp41 (HIV envelope protein). Enf prevents the fusion of HR1 domain to HR2 during HIV formation and blocks HIV infection (Teissier et al. [@CR120]). Similarly, Boceprevir and Telaprevir, both synthetic peptides against Hepatitis C virus (HCV), got approval by FDA in 2011. These peptides act on NS3/4, a protease inhibitor, and interfere with viral replication (Divyashree et al. [@CR36]). Other peptide candidates such as Myrcludex for Hepatitis B and D viruses (HBV and HDV) (Bogomolov et al. [@CR16]), Flufirvitide for Influenza virus (Skalickova et al. [@CR115]), Sifuvirtide for HIV-1 (Yu et al. [@CR138]), IM862 and SCV-07 for HCV and Thymosin α-1 for HBV as well as HCV (Jenssen [@CR62]), are under various phase trials of pre-clinical and clinical studies. We have discussed the different approaches used for the identification of AVPs. Moreover, the few selected methodologies used for the validation of identified peptides as potential AVPs have also been described here. The techniques used in identification and validation of peptides are compared in Table [1](#Tab1){ref-type="table"}.Fig. 1Different sources of antiviral peptidesTable 1Comparative analysis of selected techniques applied to identify or validate viral peptidesS. NoApproachTechniqueCharacteristicsAdvantagesDisadvantagesReferences1ComputationalDockingVirtual screening of target based hitsExpedite the process of drug discoverySize, shape, charge distribution, polarity, hydrogen bonding, and hydrophobic interactions of ligand-receptor complexes can be identifiedIdentification of target sites of the ligand and the receptor moleculeStructure--activity based studiesRequires multiple runs to obtain reliable resultsLimits the flexibility of receptorLess accurateDocking calculations are complexNevola and Giralt ([@CR89])PeptidomimeticsMimics of the natural peptidesPrevent the protein--protein/protein-peptide interaction by competitive bindingDesign the mimic of peptide with enhanced bioavailabilityOvercome the proteolytic instability of natural peptides Improved receptor selectivityOffers restricted conformational structuresTermini are exchanged with the inversion of their sequenceRequires entire understanding of target interactionSen et al. ([@CR111])2BiologicalPhage displayUtilizes phages to display foreign protein/peptideMost adopted systemRapid identification of target specific phagesSystem suitable for delivering small peptides (\< 20 aa)High throughput screening approachSelection of disease specific antigen mimicsSelection of organ specific peptidesUsed in B-cell and T-cell epitope mappingLibrary size is limited by phage transformation efficiency (\~ 10^9^)Allows only natural amino acidsComplicated affinity maturation process because of large diversity of proteins/peptides displayed on surfaceLimits the rapidity of library generationRestricts the size of expressed proteinsLimits the intractability of some targetsMatsubara ([@CR80]) and Fukunaga and Taki ([@CR41])m-RNA displayUses the transcription and translation machinery extracted from prokaryotic/eukaryotic cellsUtilizes covalent mRNA-polypeptide complexes linked through puromycinLibrary size as large as (\~ 10^12--15^)Protein expression free from cellular constraintsAllows the incorporation of unnatural amino acidsGreater diversity as transformation is not requiredIncreased probability of higher affinity hitsSolid surface based biopanning often results in non specific bindingLikely to interfere with other molecules due to single stranded form of m-RNADisplay larger proteins (\> 300 aa) with lower efficiencyNot suitable for displaying membrane bound proteinsRibonuclease free environment is requiredWang and Liu ([@CR125])Ribosome displayLiving cell free technologyUtilizes non-covalent ribosome-mRNA-polypeptide complexes for display systemLibrary size as large as (\~ 10^12--15^)Greater diversity due to not being dependent on transformation efficiencyIncreased probability of higher affinity hitsSuitable for generating toxic, proteolytically sensitive and unstable proteinsRandom mutations can be introducedAllows the incorporation of unnatural amino acidsSelection stringency is limitedSystem is very sensitive to RNase activityRibonuclease free environment is requiredDreier and Pluckthun [@CR38]Yeast displayProteins/peptides are usually fused to Aga2 protein subunit of yeastCan be displayed as N- or C-terminal fusionDisplays fully nativemonomeric as well as oligomeric proteins on their surface due to eukaryotic machineryMore diverse library as compared to phage systemLibrary size is smaller (\~ 10^6--7^) than other display systemsAllows only natural amino acidsAllows the expression of extracellular proteinsComplicated affinity maturation process because of large diversity of proteins/peptides displayed on surfaceLinciano et al. ([@CR69])3Advanced TechniquesSurface Plasmon resonance (SPR)Label-free binding techniqueQuantitatively analyzes the real time binding kinetics of two bimolecular interactionsLabel-free detectionReal-time data monitoringSensitive and accurateSmall sample quantityAbility to Handle Complex SamplesAbility to Replicate MeasurementsExpensive instrument and sensorsExpensive maintenanceLow throughputPatching ([@CR94])Biolayer interferometryOptical analytical techniqueQuantify real time binding kinetics of bimolecular interactionsLabel-free detectionReal-time data monitoringNo reference channel requiredCrude sample compatibilitySystem requires less maintenanceHigh throughputLow vibrational/mechanical noiseSimple, fast and more accurate resultsRequires immobilization of ligand to surface of tipNo temperature controlLow sensitivity as compared to SPRPoor reproducibilityRelatively high sample consumptionResults should be cross-validated with SPRShah and Duncan ([@CR113])Fluorescence Resonance Energy Transfer (FRET)Radiation less transmission of energy from donor to acceptorDistance-dependantSimple, sensitive and easily automatedNon-radioactiveHigh time resolutionHigh throughputLow reagent consumptionRequires fluorophore labeled moleculesDistance of donor--acceptor pair is limited (\< 10 nm)Rogers et al. ([@CR106])

Antiviral Peptides Designed from Computational Approach {#Sec3}
-------------------------------------------------------

Computer assisted drug designing process is based on the understanding of structural and functional aspects of the viral machinery. The rational knowledge of the viral proteins and the interactors/cellular partners assists in the selection of target protein. This approach has expedited the process of drug designing. Peptides can be identified computationally; via in silico screening using molecular docking. A docking program predicts the target site which is usually known as pocket or protrusion with hydrogen bond donors and acceptors, hydrophobic characteristics and different molecular shapes. Subsequently, library of peptides docked with these pockets results in the highest binding peptide (Nevola and Giralt [@CR89]). For example, peptides have been designed computationally using virtual docking against the surface protein of Zika virus (ZIKV) for its detection. Tetra, penta, hexa and heptapeptide libraries were docked using Open Eye Scientific Software against envelope protein of ZIKV; subsequently, eight peptides were selected. They were further tested by Direct ELISA and out of them, three were delineated with best performance for Zika detection (Mascini et al. [@CR79]). Another method is based on peptidomimetics which mimics the designed targets, prevents the interaction of proteins by competitive binding. Four putative peptide inhibitors were designed against Nipah virus (NiV) proteins using the approach of peptidomimetics and the stability of peptide-protein complexes were analysed using MD simulation (Sen et al. [@CR111]). The in silico methods (Docking and peptidomimetics) can predict the peptide sequence but further validation using in vitro/in vivo approaches is required to establish its biological activity.

Antiviral Peptides Derived from Natural Source {#Sec4}
----------------------------------------------

The peptides that exhibit immunomodulatory and inhibitory properties against infection caused by bacteria, fungi, viruses or protozoa, are expressed as naturally occurring antimicrobial peptides (AMPs). The AMPs have been extensively used as substitutes of antibiotics for bacterial infections, but recently their use has been expanded to antiviral therapeutics also (Ahmed et al. [@CR2]). The naturally occurring AVPs are amphipathic and cationic in nature with net positive charge (Bulet et al. [@CR18]). Moreover, it has been proven that the hydrophobicity of the peptides is an essential property for targeting enveloped viruses (Badani et al. [@CR12]; Wang et al. [@CR129]). These AVPs can be derived from different sources such as plants, bacteria, arthropods, amphibians, marine organisms and mammals with their varied mechanism of action (Zhang and Gallo [@CR145]). A peptide family called cyclotides derived from different plant sources has been proven successfully for their antiviral activity against HIV, Influenza virus and Dengue virus (Ireland et al. [@CR60]; Sencanski et al. [@CR112]; Gao et al. [@CR43]). The small size, cationic and amphipathic nature of the cyclotides facilitates its effective binding to the target and rupture the membrane. This allows the leakage of cell components which further leads to the cell death (Weidmann and Craik [@CR132]). In a study, kalata B1, a cyclotide isolated from the leaves of *Oldenlandia affins* plant, showed destruction of viral particle at entry step along with inhibition of viral-host membrane fusion, thus exhibiting anti-HIV activity (Henriques et al. [@CR50]). Similarly, a peptide derived from arthropod, *Hyalophora ceecropia,* known as cecropin A showed the inhibitory activity against HIV, Junin virus (JUNV) and HSV by suppression of their gene expression (Wachinger et al. [@CR124]; Albiol Matanic and Castilla [@CR5]). Moreover, in recent studies bovine lactoferrin (bLF) has showed the antiviral activity against three *Aedes* mosquito transmitted viruses: Dengue (DENV), Chikungunya (CHIKV) and Zika virus apart from anti-HBV activity established in a previous study (Li et al. [@CR67]; Carvalho et al. [@CR22]; Chen et al. [@CR27]). The bLF blocks the viral binding to its target site and thus prevents its spread to host cells. Many other AVPs originated from natural source are summarized in Table [2](#Tab2){ref-type="table"} with their varied mode of action. However, despite promising efficacy, the utility of these peptides is constrained due to weak binding, low stability, other side effects and virus resistance. The shortcomings of AVPs from natural resource need to be addressed so that they can be considered as mainstay antiviral therapeutics.Table 2Selected AVPs derived from natural sources and their mode of action against virusS. NoPeptideSourceCharacteristicsTargeted virusMode of action/ activityReferenceIPlant12 kDa peptideSeeds of *Sorghum bicolor*2 kDa, cationic and amphipathic peptideHSV-1Inhibition of cell entry by masking essential viral envelope proteinsCamargo et al. ([@CR19])2Cyclotide: vhl-1Leaves of *Viola hederaceae*31 amino acid cyclic cystine knot like peptideHIVInhibition of viral fusion by disrupting the lipid envelopeWang et al. ([@CR126])3Cycloviolacin VY1*Viola yedoensis*31 amino acid peptide, three conserved disulphide bonds, bridge like 3-D structureInfluenza H1N1Inhibition of virus at cell entryLiu et al. ([@CR72])4Kalata B1Leaves of *Oldenlandia affinis*Cyclic backbone, knot-like rigid structure, three conserved disulphide bondsHIVInhibition of viral-host membrane fusionHenriques et al. ([@CR50])5Kalata B1-inspired peptideDerivative of Kalata B1 peptideAmino acid modifications in kalata B1peptideDENVInhibition of viral replicationGao et al. ([@CR43])6Peptides 2 and 4*Acacia catechu*15 amino acids, cationic and amphipathic peptideDENVInhibition at early steps of viral entryPanya et al. ([@CR93])7SesquinSeeds of *Vignasesquipedalis*7 kDa, cationic, defensin like peptideHIVInhibition of viral replication by hindering reverse transcriptase activityJack and Tzi ([@CR61])IIBacteria8Locillomycin*Bacillus subtilis*Cyclic lipononapeptidePEDVunknownLuo et al. ([@CR76])9Surfactin*Bacillus subtilis*Cyclic lipopeptide, amphiphilicHIV, HSV-1, HSV-2, VSV, SIV, NDV, PEDVDisintegration of lipid envelope and, capsid through ion channel formationsYuan et al. ([@CR139])IIIArthropod10Alloferon 1 and 2Hemolymph of blowfly: *Calliphora vicina*Linear, nonglycosylated oligopeptide of 13 and 12 amino acid residues, respectivelyInfluenza virusInhibition by activation of natural killer cells and release of interferonChernysh et al. ([@CR28])HSV-1Inhibition of viral replication11Alloferon 1-derived peptideHemolymph of blowfly: *Calliphora vicina*Modifications in their N-terminal portions of Alloferon1 peptideCBV-2Inhibition of viral replicationKuczer et al. ([@CR63])12Bmkn2-7Venom of scorpion: *Mesobuthus martensii*13-amino acid residues, basic, alpha-helical peptideHIV-1Inhibition by direct interaction with viral particleChen et al. ([@CR26])13Cecropin AMoth *Hyalophora cecropia*37-amino acid linear, cationic peptideHIV; HSV-1 and 2; JUNVSuppression of viral gene expressionWachinger et al. ([@CR124]) and Hultmark et al. ([@CR59])14Ctry2459*Chaerilus tryznai*13-amino-acid residue, helical and amphipathic peptideHCVInhibition by inactivating the viral particles, virucidal activities and suppressed the established infection at cellular levelHong et al. ([@CR53])15Ctry2459-H2Histidine-rich Ctry2459 peptide16Ctry2469-H3Histidine-rich Ctry2459 peptide17Eva1418Venom of scorpion: *Euscorpiops validus*Helical and amphipathic peptideHSV-1Inhibition by disruption of initial steps of infectionZeng et al. ([@CR143])18Eva1418-FH5Histidine rich derivative of Eva1418 peptideEnhanced inhibition activity with lowest cytotoxicity19Hp1090Venom of Scorpion: *Heterometrus petersii*Amphipathic α-helical peptideHCVInhibition of viral replicationYan et al. ([@CR136])20Hp1239Venom of Scorpion: *Heterometrus petersii*Amphipathic α-helical peptideHSV-1Inhibition of cell entry by blocking viral-host membrane fusionHong et al. ([@CR54])21Hp103622Lactarcin 1Venom of spider: *Lachesana tarabaeve*Amphipathic α-helical peptideDENVInhibition of viral replication by binding to viral proteaseRothan et al. ([@CR108])23MastoparanVenom of wasp: *Vespula lewisii*14 amino acid residues, cationic, amphipathic α-helical peptideVSV, HSV-1, flavivirusesInhibition of cell entry by disruption of envelopeMoreno and Giralt ([@CR88])24Mastoparan 7Venom of wasp: *Vespula lewisii*Derivative of Mastoparan peptideVSVInhibition of cell entry by disruption of envelopeSample et al. ([@CR110])25MelittinVenom of bee: *Apis mellifera*26 amino acid linear cytolytic peptide with no disulfide bridgeHIV-1; HSV-1 and 2; JUNVInhibition of cell entry by disruption of envelopeAlbiol Matanic and Castilla ([@CR5]), Galdiero et al. ([@CR42]), and Hood et al. ([@CR55])26Mucroporin-M1Scorpion: *Lychas mucronatus*Cationic host defense peptideMeV, Influenza-H5N1; SARS-CoV; HIV-1Virucidal activityLi et al. ([@CR68])HBVInhibition of viral replication by decreasing expression of important HBV replication factorsZhao et al. ([@CR147])IVAmphibians27DermaseptinsS3, S4Frogs of *Phyllomedusa* genuscationic, amphipathic and α-helical peptideHSV-1 and 2, HIVInhibition at cell entry step by targeting viral envelopesLorin et al. ([@CR73])28Dermaseptin derived peptideFrogs of *Phyllomedusa* genuscationic, amphipathic and α-helical peptideRabies virusInhibition at cell entry stepVirucidal mechanism of actionBergaoui et al. ([@CR15])29HS-1Skin of Anuran: *Hypsiboas semilineatus*cationic, amphipathic and α-helical peptideDENV 2 and 3Inhibition at cell entry step by targeting viral envelopesMonteiro et al. ([@CR87])30Magainin I and IIFrog: *Xenopus laevis*23 amino acid residues, lysine-rich, cationic, amphipathic and α-helical peptideHSV-1 and 2Inhibition at cell entry step by disrupting the structure of viral envelope proteins; virucidal activityAlbiolMatanic and Castilla (2004)31Magainin-II derived peptideFrog: *Xenopus laevis*alanine-substituted magainin-2 amide along with three other peptidesVVVirucidal activity by attacking its envelope32Temporin BFrog: *Rana temporaria*10--50 amino acids, cationic, amphipathic and α-helical peptideHSV-1Inhibition at entry step by interfering in cell-to-cell spread of the virus33UruminIndian frog: *Hydrophylax bahuvistara*27-residues, cationic, amphipathic and α-helical peptideInfluenza-H1N1 and H1N2Inhibition at cell entry step by targeting cell receptorsHolthausen et al. ([@CR52])VMarine organisms34Callipeltin A*Callipeltin sp.*Cyclic depsidecapeptideHIV-1Inhibition of virion entryZampella et al. ([@CR141])35Celebeside A-C*Siliquariaspongia mirabilis*Cyclic depsipeptidesHIV-1Inhibition of virion entryPlaza et al. ([@CR97])36Clavanin ATunicate: Styelaclava23 residues alpha-helical peptide with amidated C-terminalRotavirusDenovirusInhibition by interfering with viral membranesCarriel-Gomes et al. ([@CR21])37Homophymine A*Homophymia sp.*Cyclic depsipeptideHIV-1Inhibition of virion entryZampella et al. ([@CR142])38Koshikamides F*Theonella swinhoei*17-residue cyclic depsipeptidesHIV-1Inhibition by blocking HIV entry into T cellsPlaza et al. ([@CR98])39Koshikamides H*Theonella cupola*17-residue cyclic depsipeptidesHIV-1Inhibition by blocking HIV entry into T cells40LvHcL48Hemocyanin of shrimp: *Litopenaeus vannamei*79 amino acid fragmentWSSVInhibition of the transcription and proliferation possibly by binding to the viral envelope proteinZhan et al. ([@CR144])41Microspinosamide*Sidonops microspinosa*cyclic depsipeptide incorporating 13 amino acid residuesHIVInhibition of cytopathic effects of the infectionRashid et al. ([@CR103])42Mirabamide A, C and DSiliquaria spongia mirabilisCyclic depsipeptidesHIV-1Inhibition at the early stages of virus entryPlaza et al. ([@CR96])43MirabamidesE, F, G, and HSponge: *Stelletta clavosa*Cyclic depsipeptidesHIV-1Inhibition at entry step by disruption of viral membrane fusionLu et al. ([@CR74])44Mollamides BTunicate: *Didemmummolle*Cyclic hexapeptideHIVunknownDonia et al. ([@CR37])45Mutremdamide A*Theonella swinhoei*Sulfated cyclic depsipeptideHIV-1Inhibition by blocking HIV entry into T cellsPlaza et al. ([@CR98]46Neamphamide A*Neamphius huxleyi*Cyclic depsipeptideHIV-1Inhibition of virion entryOku et al. ([@CR91])47Nkl~71-100~Turbot: *Scophthalmus maximus*five-helix bundled structure stabilized by three intra chain disulphide bondsSVCInhibition by not binding of viral particles to host cells and fusion of virus and cell membranesFalco et al. ([@CR39])48Papuamide ATunicate: *Didemmum molle*Cyclic depsipeptidesHIVvirucidal mechanismAndjelic et al. ([@CR10])49Piscidin 1Mast cells of hybrid Striped bass (fish)22 amino acid, α--helical and amphipathic peptidePRVInhibition by direct interaction with virusHu et al. ([@CR58])50Pa-MAP 1Polar fish: *Pleunorectus americanus*an alanine-rich α-helix peptide composed of eleven amino acid residues with three imperfect motif repetitionsHSV-1 and 2Virucidal mechanism of action, Inhibition at entry step by interacting viral surface glycoproteinMigliolo et al. ([@CR85])51P34Intestinal contents of *Leporinus* sp. (fish)Anionic, thermostable, hydrophobic, lipidic peptideEAV, FHV-1Virucidal activityCastro et al. ([@CR23])BoHV-1Inhibition of the viral penetrationCastro et al. ([@CR24])52Stellettapeptin A and B*Stelletta clavosa*Cyclic and nonribosomal depsipeptidesHIV-1Inhibition of cytopathic effects of the infectionShin et al. ([@CR114])53TheopapuamideA*Theonella swinhoei*Cyclic depsipeptidesHIV-1Inhibition of virion entryAndjelic et al. ([@CR10])54Theopapuamide B-D*Siliquariaspongia mirabilis*undecapeptides with an N-terminal fatty acid moietyHIV-1Inhibition by disruption of viral membranePlaza et al. ([@CR97])VIMammals55α-Defensin HNPs 1, 2 and 4Human neutrophil18 to 45 amino acid residuescationic charge, amphipathic properties and predominance of β sheets stabilized by three disulfide bondsHIV-1Inhibition at cell entry stepWu et al. ([@CR133])56α-Defensin HNPs 1Human neutrophilInfluenza AInhibition of viral replicationSalvatore et al. ([@CR109])57β-defensins hDB-2Epithelial cellscysteine-rich, cationic peptidesHPV; VZV; HIVInhibition at cell entry as well as viral replication by late reverse transcripts and nuclear importMeyer-Hoffert et al. ([@CR84]) and Crack et al. ([@CR32])58β-defensins hBD-3Epithelial cellsHPV; VV; VZV; HIVInhibition of viral replicationQuinones-Mateu et al. ([@CR99]), Howell et al. ([@CR57]), Gwyer Findlay et al. ([@CR47])59Cathelicidin LL-37Human neutrophil granules12 to 88 amino acid residues, cationic, α-helical and amphipathic peptideVZV; VV; HSV-1; HIV; RSV; Influenza A; HCV; DENV; ZIKV; VEEVInhibition of cell entry by disruption of envelopeSørensen et al. ([@CR116]), Barlow et al. ([@CR14]), Tripathi et al. ([@CR122]), Matsumura et al. ([@CR82]), Alagarasu et al. ([@CR4])Adenovirus; Aichi virus; RhinovirusInhibition of cell entryGordon et al. ([@CR45]), Sousa et al. ([@CR117]), Ahmed et al. ([@CR3])60CYVIPHuman hemofiltrate71-amino-acid, cationic peptideHCMVHSV-1Inhibition of cell entry by interacting the host cell receptorsBorst et al. ([@CR17])61IndolicidinBovine neutrophilsTridecapeptide amideHIVInhibition by membrane-disruptionRobinson et al. ([@CR105])62LactoferrinMammals' milkHydrophobic, cationic, and helical peptideCMV; HSV-1and 2; Adenovirus; Rotavirus; Poliovirus; RSV; HIV; Influenza; HCV; HBV DENV; CHIKV; ZIKVInhibition at cell entry as well as viral replicationVan der Strate et al. ([@CR123]), Li et al. ([@CR67]), Carvalho et al. ([@CR22]), Chen et al. ([@CR27])63LactoferricinDerivative of lactoferrinAmphipathic, cationic peptide corresponds to lactoferrin fragment 17--41CMV, HIV-1, HPVInhibition at cell entry stepAndersen et al. ([@CR9]), Mistry et al. ([@CR86]), Li et al. ([@CR67]), Wang et al. ([@CR128])HSV-1and 2Inhibition of viral replication by interfering the host cell microtubulesMarr et al. ([@CR78])64Protegrin-1White blood cells of swine18 amino acid residues, cyclical, β -sheets and cationicDENVInhibition of viral replication by binding to viral proteaseRothan et al. ([@CR107])Human immunodeficiency virus: HIV; Dengue virus: DENV; Herpes simplex virus 1 and 2: HSV-1 and HSV-2; Porcine epidemic diarrhea virus: PEDV; Vesicular stomatitis virus: VSV; Simian immunodeficiency virus: SIV; Newcastle disease virus: NDV; Coxsackie virus B2: CBV-2; Junin virus: JUNV; Hepatitis C virus: HCV; Measles morbillivirus: MeV; Severe acute respiratory syndrome coronavirus: SARS-CoV; Hepatitis B virus: HBV; Vaccinia virus: VV; White spot syndrome virus: WSSV; Carp sprivivirus: SVC; Pseudorabies virus: PRV; Equine arteritis virus: EAV; Feline herpes virus type-1: FHV-1; Bovine herpesvirus1: BoHV-1; Human papillomavirus: HPV; Varicella zoster virus: VZV; Respiratory syncytial virus: RSV; Zika virus: ZIKV; Venezuelan equine encephalitis virus: VEEV; Human cytomegalovirus: HCMV; Cytomegalovirus: CMV; Chikungunya virus: CHIKV

Antiviral Peptides Identified Through Biological Approach {#Sec5}
---------------------------------------------------------

Methodologies based on in vitro display approach, usually offer genetically encoded peptides with superior quality and high affinity to their targets. Among these methodologies, phage display, mRNA display, ribosome display, yeast display and bacteria display are the most common technologies to generate peptides. The phage display technology is widely used and considered as the most appropriate for the screening of high efficiency peptides. While these technologies have already been thoroughly illustrated in other reviews (Nevola and Giralt [@CR89]), we have focused on the use of selected methodologies for the identification of antiviral peptides and compared them in Table [1](#Tab1){ref-type="table"}.

### Phage Display {#Sec6}

Phage display technology is an efficient in vitro screening method for the selection of high affinity and target specific peptide binder from a randomly displayed peptide library. The technology involves the fusion of exogenous peptide sequence into the genome of phage, its expression on the surface as fusion product to phage surface protein. The phage displayed libraries thus constructed have 10^9--10^ variants at a time. In this method, biopanning is performed in which the target molecule is immobilized on surface and incubated with phage library. The unbound or excess of phage particles are removed by washing and potentially bound phages are eluted by acidic/basic buffer or with appropriate ligand. These recovered phages are amplified by infecting bacterial cells *Escherichia coli* and are used for subsequent rounds of biopanning to obtain target specific phages using affinity selection. The sequencing of DNA isolated from binding phage, validated by ELISA, helps to identify peptide sequence (Fukunaga and Taki [@CR41]; Matsubara [@CR80]). A peptide named P3 against Japanese encephalitis virus (JEV) host fusion has been identified as the potential AVP using phage display library. The screened peptide has shown the highest affinity to domain III of JEV envelope glycoprotein assessed by Biolayer interferometry and IC~90~ of \~ 100 µM and IC~50~ of \~ 1 µM in JEV infected BHK-21 cells (Wei et al. [@CR131]). Similarly, an analogous study conducted by de la Guardia et al. ([@CR33]) identified three peptides against the domain III of DENV envelope protein to block the DENV infection. Further these peptides were non-toxic to the target cells. Moreover, the same approach has also been used to identify peptides targeting non-structural viral protein: RNA-dependent RNA polymerase (NS5B) of HCV, by screening a library composed of disulfide-constrained heptapeptides (Amin et al. [@CR7]). In another study, a novel heptapeptide was identified using random peptide phage library which inhibited the integration of HIV genome into the host (Desjobert et al. [@CR35]). The most important advantage of this technology over others is its high rate of mutability with affinity selection, which widely employs the screening of phage displayed peptides for identification of potential AVPs. There are many other AVPs derived from the utilization of phage display technology which are summarised in Table [3](#Tab3){ref-type="table"}.Table 3Characteristics of the AVPs derived from Phage display technologyS. NoPeptide sequenceLibrary usedTargeted virusTargeted proteinReferences1GSHHRHVHSPFV12-mer peptide library: New England Biolabs (NEB)Avian infectious bronchitis virusPurified whole virusPeng et al. ([@CR95])2HAWDPIPARDPF12-mer peptide library (NEB)Avian influenza A virus-subtype H5N1H5N1 virusesWu et al. ([@CR135])3AAWHLIVALAPN4ATSHLHVRLPSK5NDFRSKT7-mer disulfide constrained peptide library (NEB)Avian influenza virus H9N2AIV sub-type H9N2 virus particlesRajik et al. ([@CR101])6HSIRYDF7-mer peptide Library (NEB)Bovine ephemeral fever virusNeutralization site 1 of glycoprotein: G1Hou et al. ([@CR56])7YSLRSDY8DRATSSNAOctapeptides peptide libraryClassical swine fever virusEnvelope protein: E2Yin et al. ([@CR137])9SYQSHYY7-mer peptide Library (NEB)Dengue virusRecombinant dengue envelope protein and its domain IIIde la Guardia et al. ([@CR33])10STSFWIT11ELLASPW12CWSFFSNIC7-mer disulfide constrained peptide library (NEB)Hepatitis B virusFull-length HBcAgHo et al. ([@CR51])13KHMHWHPPALNT12-mer peptide library (NEB)Hepatitis B virusPreS1 region of L-proteinWang et al. ([@CR127])14WTDMFTAWWSTPM13-based 12-mer peptide libraryHepatitis B virusThio-PreSDeng et al. ([@CR34])15FPWGNTW7-mer disulfide constrained peptide library (NEB)Hepatitis C virusNS5B (del 21-His) proteinAmin et al. ([@CR7])16ATWVCGPCTPhage-displayed nonapeptide library (PVIII9aa)Hepatitis C virusmAb JS-81 against CD81Cao et al. ([@CR20])17WPWHNHRheptapeptide M13 phage-display libraryHepatitis C virusTruncated envelope protein E2Lu et al. ([@CR75])18RINNIPWSEAMMlibraries of random 12-mers, 7-mers, and cyclic 9-mersHuman immunodeficiency virusEnvelope glycoprotein gp120Ferrer and Harrison ([@CR40])19VSWPELYKWTWS7-mer disulfide constrained peptide library; 12-mer peptide library (NEB)Human immunodeficiency virusmAb VRC01Chikaev et al. ([@CR30])20FHNHGKQ7-mer peptide library (NEB)Human immunodeficiency virusHIV-1 IntegraseDesjobert et al. ([@CR35])21GWWYKGRARPVSAVAPentadecapeptides peptide libraryInfluenza virus AMonolayer of the ganglioside:GM3Matsubara et al. ([@CR81])22RAVWRHSVATPSHSV23SENRKVPFYSHS12-mer peptide library (NEB)Japanese encephalitis virusDomain III of the virus envelope glycoproteinZu et al. ([@CR148])24TPDCTRWWCPLT12-mer peptide library (NEBJapanese encephalitis virusE proteinWei et al. ([@CR131])25RLNNRARIILRA12-mer peptide library (NEB)Mink enteritis virusPurified whole virusZhang et al. ([@CR146])26LAHKSRLYERHM27CTLTTKLYC7-mer disulfide constrained peptide library (NEB)Newcastle disease virusInactivated whole virusRamanujam et al. ([@CR102])28EVSHPKVGHeptapeptide library-pSKAN8-HyA libraryNewcastle disease virusInactivated whole virusOzawa et al. ([@CR92])29SGGSNRSP30WVTTSNQW31IQTAFNQGA7-mer disulfide constrained peptide library (NEB)Porcine reproductive and respiratory syndrome virusmAb N3H2 against nucleocapsid proteinLiu et al. ([@CR71])32HRILMRIR12-mer peptide library (NEB)Porcine reproductive and respiratory syndrome virusORF1bAn et al. ([@CR8])33CHWMFSPWCRandom heptapeptide libraryflanked by cysteinesPuumala orthohantavirusInactivated whole virusHeiskanen et al. ([@CR48])34TATTEK12-mer peptide library (NEB)West Nile virusNon-structural protein 1Sun et al. ([@CR118])35VVDGPETKEC36P9 peptidePeptide library (Spring Bioscience)West Nile virusRecombinant E proteinBai et al. ([@CR13])

### mRNA Display {#Sec7}

mRNA display technology utilizes the covalently bonded mRNA-polypeptide complexes formed during in vitro translation, which are linked through puromycin (an analogue of the 3′tyrosyl-tRNA along with mimics of adenosine and tyrosine) via A- site of ribosome. The complexes with desired functions are allowed to bind to the immobilized target protein, reverse transcribed to cDNA and amplified via Polymerase chain reaction (PCR). This enables the reinforcement of DNA template library for next round of screening (Cotten et al. [@CR31]; Newton et al. [@CR90]). The most successful use of mRNA displayed peptide library was described by Litovchick and Szostal ([@CR70]), in which they have screened potential AVPs using cyclic peptide-mRNA fusion library targeting Internal ribosomal entry site (IRES) of HCV for inhibition of virions. Another use of this technology was reported for the reverse engineering of peptide vaccines for HCV. High affinity peptides to neutralizing monoclonal antibodies (mAbs) of HCV were selected in this study and used for peptide-based vaccine development (Guo et al. [@CR46]).

### Ribosome Display {#Sec8}

Ribosome display is an entirely in vitro and cell-free system which makes it efficient in comparison to other display systems (Nevola and Giralt [@CR89]). In this system, the coupling of genotype and phenotype is essential for the selection of high affinity peptides from their pool. During in vitro translation, the association between the mRNA, ribosome and the nascent polypeptide leads to a stabilized protein-ribosome-mRNA complex. This ternary complex is feasible due to the presence of spacer sequence, without stop codon, inserted into the DNA library coding for proteins/ peptides. The spacer ensures that the peptide folds properly and stays attached to the mRNA and ribosomes. These specific ribosomal complexes that display folded peptides are then allowed to bind to the immobilized target and the non-specific ones are washed off. The mRNA complexes having bound polypeptide chains are recovered and their sequences are obtained (Zahnd et al. [@CR140]). A large library that contains 10^13^--10^14^ clones can be screened as it is not dependent on the living cell system and is free of any bias. This technology has numerous advantages above others as the diversity of library depends on the number of available ribosomes and mRNA in the system rather restricted by the bacterial transformation efficiency (Dreier and Pluckthun [@CR38]). Moreover, such system allows insertion of random mutations at any round of selection since library has not been transformed after any diversification step. The ribosomal display technology has opened a new insight for using peptide inhibitors for early diagnostic as well as therapeutic agent. For instance, the peptide inhibitor against envelope protein E2 of HCV was identified using ribosomal display library. After extensive selection of 13 rounds, 12-mer peptides were generated. This peptide named PE2D has not only being verified to bind E2 protein but also blocks the virus entry inside hepatocyte cells (Chen et al. [@CR25]).

### Yeast Display {#Sec9}

The main advantage of the yeast display system over the others is the complete exposure of the peptides/protein for fusion and its compatibility with the fluorescence-activated cell sorting (FACS), which enables the high-throughput screening and characterization of protein/peptide combinatorial libraries (Linciano et al. [@CR69]). Moreover, it also allows the expression of proteins with post translational modifications which has encountered the problem of misfolding in the field of antibody engineering (Mei et al. [@CR83]). *Saccharomyces cerevisiae* strain based on the Aga1--Aga2 proteins is the most widely used display system. In this system, the protein/peptide is displayed either as N- or C-terminal fusion to the Aga2 protein of yeast cell, which is linked to the Aga1 via disulphide bonds. Every yeast cell exhibits \~ 10^4^--10^5^ copies of the Aga2 fusion protein/peptide on its surface though the expression of individuals may vary. The construct of yeast cell also contains two epitope tags at the N and C terminus of Aga2 fusion protein, which facilitates the real time quantification of their expression using flow cytometry. Moreover, the tags also enable to estimate and quantify the binding of the target via different labelling approaches (Linciano et al. [@CR69]). Though yeast display system is a valuable platform for screening purpose, however, the library size is restricted due to limited transformation efficiency of yeast. Another major limitation of yeast display is complicated affinity maturation process in comparison to other systems. Besides, these drawbacks, this technology has provided a wide application of high throughput screening in peptide engineering and a platform to study protein--protein/peptide interactions in vivo. In a recent study, this technology was used to screen the hits from a grafted C-peptide library of HIV gp41 against N-peptide trimer of HIVgp41. As a result, four hits suppressed the HIV entry better than others (Tennyson et al. [@CR121]).

Application of Advanced Techniques to Validate Identified Peptides {#Sec10}
==================================================================

Another challenging task in the intervention of antiviral peptides is the corroboration of the binding of selected peptides to the target protein, and their antiviral efficacy. Various techniques have been developed to evaluate the PPIs in vitro*/*in vivo such as Surface Plasmon Resonance (SPR), Optical based Biolayer interferometry, Fluorescence Resonance Energy Transfer (FRET), Nuclear Magnetic Resonance (NMR), Isothermal Calorimetry (ITC), yeast two hybrid display, microscopic visualization and many more. Some of them can be used for the binding evaluation of the peptides to their target proteins. Since various reviews and reports are available on PPIs detection methods in detail (Nevola and Giralt [@CR89]), this review focuses only on the recent techniques used to determine/ validate the peptide binding efficiency (Table [1](#Tab1){ref-type="table"}).

Surface Plasmon Resonance (SPR) {#Sec11}
-------------------------------

SPR is an optical based detection and label-free technique which utilizes the protein in small amount for the real time quantification and evaluation of the binding affinity as well as kinetics between peptide and target protein (Patching [@CR94]). The binding affinity between interacting partners is measured via small variation in the refractive index at sensor surface. This response change is calculated as the change in the angle of resonance of refracted light when flowing analyte binds to the immobilized ligand. The change in the angle of resonance is measured in the form of resonance unit (RU), where 1RU is equivalent to the 10^--4^ deg/10^--12^ gmm^−2^ angle shift. It has become the gold standard in research, typically characterizes the interaction between two molecules in which one is in mobile state and the other is fixed on a gold film. This technique can be used to screen the library of molecules for their binding affinity against a single soluble protein which is immobilized on the sensor surface (Tang et al. [@CR119]). Thus, SPR has emerged as a powerful technique in therapeutic intervention. It can also be adapted to study the interactions involving complicated proteins in situ*,* such as, membrane-bound proteins, ion channels and other growth, immune and cellular receptors, which are considered as potential targets for drug discovery (Patching [@CR94]). Bai et al. ([@CR13]) have investigated the affinity interaction of screened peptides to the Envelope protein of West Nile virus (WNV) using SPR, in which they found peptide P9 to have the highest affinity to the target. Besides this, in another study, the binding of Helix-A peptide to the neuronal microtubules (MTs): β-tubulin was determined by SPR. Helix-A peptide prevents the binding of the gp120 protein of HIV to the β-tubulin, a neuronal MT and possesses neuroprotective activity (Avdoshina et al. [@CR11]). Moreover, the SPR has been used as a ligand screening strategy for Influenza virus and HSV-1, in which the technique enables the continuous screening of inhibitors that inhibit the viral entry. The major advantage of this technique is the use of minimal amount of immobilized viral surface proteins or receptors as compared to other techniques (Kumar [@CR64]).

Biolayer Interferometry {#Sec12}
-----------------------

Another optical based and label-free technique is the Biolayer interferometry (BLI) which validates the interaction between two molecules by quantifying the change in an interference pattern. The target molecule is immobilized on the tip of fiber optic biosensor that moves toward the wells containing the binding partner present in solution. The association and dissociation of the binding partner with the immobilized molecule is monitored by BLI, leading to the generation of optical thickness at the tip of biosensor that produces an optical interference pattern. This pattern can be quantified and used to determine real time kinetic rates of binding and dissociation (Shah and Duncan [@CR113]). Thus, it has become a valuable tool for monitoring interactions between small molecules in the field of drug discovery. This technique is advantageous over others as nonspecific and non ideal interactions can be differentiated in initial steps by examining their binding response and moreover, it has low false positive rate. Besides, the varied flow rate, available unbound molecules and the refractive index of adjacent medium do not affect the obtained interference pattern, which is the unique property of this technique (Wartchow et al. [@CR130]). In this context Zu et al. ([@CR148]) have analysed the real time binding affinity of chemically synthesized screened peptides to the Domain III of JEV envelope protein and reported peptide P3 possessed the highest affinity.

Fluorescence Resonance Energy Transfer (FRET) {#Sec13}
---------------------------------------------

FRET is a sensitive method to investigate the interaction of proteins with large diverse set of peptides/proteins libraries for high throughput screening efficiently. This technique is reliable on the distance-dependent transfer of energy between dye-labelled molecules, where the excited donor fluorophore transfers its energy to an acceptor chromophore (Rogers et al. [@CR106]). This energy transfer determines the ratio metric signal generated by the reduction in fluorescence of donor molecule and the increment in fluorescence of acceptor molecule. The technique of FRET can be used as both screening as well as validation method. In view of this, various FRET based studies have been reported for the identification of potent inhibitors against several viral proteases such as SARS coronavirus 3CLpro protease, DENV NS2B-NS3 protease, WNV Serine Protease, HCV NS3/4A protease and HIV protease. Similarly, a FRET based proteolytic assay was used to screen the compounds against CHIKV capsid protein (Aggarwal et al. [@CR1]).

Challenges to the Peptide as Therapeutic Use {#Sec14}
============================================

Several limitations that obstruct the way of peptide to be a successful therapeutic drug, are its instability, short half-life, lower potency, inability to cross membrane barriers and poor bioavailability due to protease degradation (Ali et al. [@CR6]). The main challenge is to overcome these limitations and to achieve the desired efficacy for the required time span. Various modifications have been employed to enhance the stability and physiochemical properties of the peptides (Gentilucci et al. [@CR44]). For instance, the conjugation of peptide to polymers such as polyethylene glycol (PEG) has enhanced the stability of peptides by increasing their molecular weight (Chew et al. [@CR29]). Likewise, the bioavailability was improved by balancing the aqueous solubility via replacement of redundant hydrophobic amino acids to charged/polar residues (Mant et al. [@CR77]; Wu et al. [@CR134]). Moreover, there are two computational softwares based on support-vector machine (SVM) to predict the solubility of the peptides, thus assisting in the designing and optimising the peptide bioavailability (Lee et al. [@CR66]). In addition to the strategies involved in the improvement of peptide properties, the delivery of peptides has also been improved by linking of peptides to the cell penetrating peptides (CPPs) to enhance their cell permeability (Chew et al. [@CR29]). CPPs are general peptides (\< 30 amino acids) derived from natural/unnatural sources or chimeric sequences, considered as promising carrier for successful delivery of therapeutic molecules varying from small chemical molecules, liposomes, proteins, peptides and nucleic acids for in vitro as well as in vivo applications (Heitz et al. [@CR49]). Alternatively, peptides can be encapsulated in nanoparticles for efficient delivery, or administered through primary parental or transdermal routes with variations such as prefilled syringes, auto injectors and biodegradable micro needles (Lee et al. [@CR66]). These modifications help to address the challenges of poor ADME properties of non-modified peptides (Lau and Dunn [@CR65]).

Conclusion {#Sec15}
==========

In summary, the discovery of the peptide-based therapies have made a significant impact in the research. Many peptide therapies are available in the clinical and pre-clinical trials which are expected to yield positive results. The various approaches including computational, natural and biological sources provide a wide repository for identification of peptides involved in viral therapeutics. These promising therapeutics/inhibitors are advantageous because of their high specificity, selectivity against target and can be easily developed without the prior structural knowledge of target (except docking). Novel technologies like SPR, BLI and FRET validate the binding of identified peptides to their target which further aid in the selection of high affinity potential AVPs. However, there is a dearth of knowledge in the field of identification and characterization of antiviral therapeutics; further advancement and commercialization of peptide-based therapeutics is warranted.
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